VisEn Medical, a developer of agents and systems in the field of molecular imaging, has a new partner. Siemens has taken an equity stake in the company in an effort to promote the development of MI technology and expand the markets for in vivo imaging of
VisEn Medical, a developer of agents and systems in the field of molecular imaging, has a new partner. Siemens has taken an equity stake in the company in an effort to promote the development of MI technology and expand the markets for in vivo imaging of molecular events. VisEn, which was founded in June 2000 on technologies developed at Massachusetts General Hospital and Harvard Medical School, is focusing on technology for imaging cancer, atherosclerosis, and rheumatoid arthritis.
